Eli Lilly (LLY) Common Equity (2009 - 2026)

Eli Lilly (LLY) has 18 years of Common Equity data on file, last reported at $31.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 106.61% year-over-year to $31.2 billion; the trailing twelve-month figure through Mar 2026 stood at $31.2 billion (up 106.61% YoY), and the FY2025 full-year result was $26.5 billion, up 1210.25% from the prior year.
• Common Equity for Q1 2026 stood at $31.2 billion, up from $26.5 billion in the prior quarter.
• Across five years, Common Equity topped out at $31.2 billion in Q1 2026 and bottomed at -$3.8 billion in Q4 2022.
• The 5-year median for Common Equity is -$2.2 billion (2025), against an average of $4.6 billion.
• Peak annual rise in Common Equity reached 46277.37% in 2025, while the deepest fall reached 6607.65% in 2025.
• A 5-year view of Common Equity shows it stood at -$3.8 billion in 2022, then grew by 29.86% to -$2.7 billion in 2023, then advanced by 11.38% to -$2.4 billion in 2024, then surged by 1210.25% to $26.5 billion in 2025, then increased by 17.57% to $31.2 billion in 2026.
• The last three Common Equity figures came in at $31.2 billion (Q1 2026), $26.5 billion (Q4 2025), and $23.8 billion (Q3 2025), per Business Quant data.

Peer Comparison